onc Videos

Videos

Michail Ignatiadis, MD, PhD, Jules Bordet Institute

Videos

No Benefit From Addition of Atezolizumab to Adjuvant Chemotherapy Among Patients with Triple-Negative Breast Cancer

12/07/2023

Featuring Michail Ignatiadis, MD, PhD

Featuring Michail Ignatiadis, MD, PhD...

Michail Ignatiadis, MD, PhD, discusses the interim analysis of a phase 3 trial which found adding atezolizumab to adjuvant chemotherapy was very unlikely to provide benefit to patients with triple-negative breast cancer.

Michail Ignatiadis, MD, PhD,...

12/07/2023

Oncology

Conference Coverage

Front-Line Treatment Options for Ovarian Cancer

12/07/2023

Featuring Bradley Monk, MD

At the Great Debates & Updates in Women’s Oncology meeting, Bradley Monk, MD, discussed molecular testing and advancements in front-line treatment for patients with advanced epithelial ovarian cancer.

At the Great Debates & Updates...

12/07/2023

Oncology

Conference Coverage

Datopotamab Deruxtecan for Patients With Previously Treated, Inoperable, or Metastatic HR-Positive, HER2-Negative Breast Cancer

12/07/2023

Featuring Aditya Bardia, MD, MPH

Featuring Aditya Bardia, MD, MPH ...

Aditya Bardia, MD, MPH, discussed results from the TROPION-Breast01 trial comparing datopotamab deruxtecan, a TROP-2 directed antibody drug conjugate, with standard chemotherapy in endocrine-resistant metastatic breast cancer.

Aditya Bardia, MD, MPH,...

12/07/2023

Oncology

Conference Coverage

Palbociclib Plus Fulvestrant or Letrozole for HR-Positive, HER2-Negative Advanced Breast Cancer

12/07/2023

Featuring Antonio Llombart-Cussac MD, PhD

Featuring Antonio Llombart-Cussac MD,...

Antonio Llombart-Cussac MD, PhD, discussed extended follow-up results from the phase 2 PARSIFAL study combining the CDK4/6 inhibitor palbociclib with either fulvestrant or letrozole.

Antonio Llombart-Cussac MD, PhD,...

12/07/2023

Oncology

Conference Coverage

Efficacy, Safety of Toripalimab Plus Metronomic Chemotherapy for HER2-Negative Metastatic Breast Cancer

12/07/2023

Featuring Hongnan Mo, MD

Hongnan Mo, MD, discussed results from a phase 2 study comparing metronomic chemotherapy plus PD-1 blockade to combined conventional chemotherapy plus immune checkpoint blockade.

Hongnan Mo, MD, discussed...

12/07/2023

Oncology

Cynthia Ma, MD; Neelima Vidula, MD; Seth Wander, MD

Videos

Selecting CDK4/6 Inhibitors for Patients With ER-Positive Early Breast Cancer

12/07/2023

Featuring Cynthia Ma, MD; Neelima Vidula, MD; Seth Wander, MD

Featuring Cynthia Ma, MD; Neelima Vid...

Cynthia Ma, MD, leads part 2 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting CDK4/6 inhibitors for patients with ER-positive early breast cancer.

Cynthia Ma, MD, leads part 2 of...

12/07/2023

Oncology

Sara Hurvitz, MD, Fred Hutchinson Cancer Center

Videos

Tucatinib Plus Trastuzumab Emtansine Improved Progression-Free Survival Among Patients With HER2-Positive Metastatic Breast Cancer

12/06/2023

Featuring Sara Hurvitz, MD

Sara Hurvitz, MD, shares results from the HER2CLIMB-02 trial evaluating tucatinib plus trastuzumab emtansine among patients with previously-treated HER2-positive metastatic breast cancer.

Sara Hurvitz, MD, shares results...

12/06/2023

Oncology

Videos

Selecting Chemotherapy for Patients With ER-Positive Early Breast Cancer

11/30/2023

Featuring Cynthia Ma, MD; Neelima Vidula, MD; and Seth Wander, MD

Featuring Cynthia Ma, MD; Neelima Vid...

Cynthia Ma, MD, leads part 1 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting chemotherapy as a treatment option for patients with ER-positive...

Cynthia Ma, MD, leads part 1 of...

11/30/2023

Oncology

Videos

Evaluating the Addition of Ibrutinib to Standard Chemotherapy for Follicular Lymphoma or MZL

11/27/2023

Featuring Gilles Salles, MD, PhD

Featuring Gilles Salles, MD, PhD ...

Gilles Salles, MD, PhD, highlights findings from the phase 3 SELENE trial, which aimed to assess the value of adding ibrutinib to chemotherapy among patients with previously treated follicular lymphoma or marginal zone lymphoma.

Gilles Salles, MD, PhD,...

11/27/2023

Oncology

Videos

Minimizing Risk of Adverse Events and Transformation Among Patients With Follicular Lymphoma

11/27/2023

Featuring Abhay Singh, MD

Abhay Singh, MD, shares advice for fellow oncologists treating patients with follicular lymphoma aiming to minimize the risk of adverse events and disease transformation to AML/MDS.

Abhay Singh, MD, shares advice...

11/27/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology